Health Care [ 9/12 ] | Biotechnology [ 56/73 ]
NASDAQ | Common Stock
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer.
Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus.
The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025.
Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 26, 25 | -3.14 Decreased by -1.15 K% | -0.70 Decreased by -345.91% |
| Mar 25, 25 | -0.07 Increased by +95.63% | -0.15 Increased by +53.33% |
| Oct 31, 24 | -0.04 Increased by +80.95% | -0.31 Increased by +87.10% |
| Aug 14, 24 | -0.12 Increased by +42.86% | -0.39 Increased by +69.23% |
| May 28, 24 | 0.30 Increased by +225.00% | -0.56 Increased by +153.57% |
| Mar 26, 24 | -1.60 Increased by +44.83% | -1.60 |
| Dec 19, 23 | -0.21 Increased by +12.50% | -0.19 Decreased by -10.53% |
| Aug 18, 23 | -0.21 Decreased by -5.00% | -0.21 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 122.00 K Increased by +139.78% | -1.58 M Decreased by -232.33% | Decreased by -1.30 K% Decreased by -155.19% |
| Dec 31, 24 | 122.00 K Increased by +65.77% | -3.63 M Increased by +20.42% | Decreased by -2.97 K% Increased by +51.99% |
| Sep 30, 24 | 3.03 M Increased by +N/A% | -1.94 M Increased by +65.81% | Decreased by -64.14% Decreased by N/A% |
| Jun 30, 24 | 153.89 K Increased by +N/A% | -6.19 M Decreased by -8.98% | Decreased by -4.02 K% Decreased by N/A% |
| Mar 31, 24 | 50.88 K Increased by +N/A% | 1.19 M Increased by +119.13% | Increased by +2.35 K% Decreased by N/A% |
| Dec 31, 23 | 73.60 K Increased by +N/A% | -4.56 M Increased by +33.64% | Decreased by -6.20 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.68 M Increased by +1.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.68 M Decreased by -19.19% | Decreased by N/A% Decreased by N/A% |